Objective: To study the indication of human recombinant luteinizing hormone(r-hLH) in GnRH antagonist protocol. Methods: Retrospective analysis. All the patients using GnRH antagonist protocol were enrolled in this study from Aug,2008 to Aug,2010. This study was divided into two parts. ① The first part enrolled 107 patients with ovarian hypofunction (FSH≥10U/L or antral follicle count≤6),80 of them without supplementation of r-hLH (group A),27 of them received r-hLH together with GnRH antagonist (group B). ② The second part enrolled 71 patients using r-hLH supplementation and GnRH agonist triggering,47 of them had normal ovary function (group C),and 24 of them had ovarian hypofunction (group D). The outcomes include mature oocytes rate,fertilization rate,cleavage rate,high-quality embryo rate,biomedical pregnancy rate,implantation rate and clinical pregnancy rate. Results: ① In group B,implantation rate(29.41% vs 19.46%) and clinical pregnancy rate (44.44% vs 31.25%) were higher than group A,but there were no statistical significance. IVF mature oocytes rate and E2/≥14mm follicle of group A was significantly higher than group B. ② In group D,IVF mature oocytes rate (100.00% vs 93.71%),IVF fertilization rate(79.52% vs 38.46%) and ICSI fertilization rate (84.85% vs 42.74%) were significantly higher than group C. In group D,implantation rate (28.89% vs 17.44%) and clinical pregnancy rate (41.67% vs 25.53%) were higher than group C,but there were no statistical significance. Conclusions: Recombinant human luteinizing hormone supplementation to GnRH antagonist protocol can improve ovary response and pregnancy outcome of ovarian hypofunction women. There has no reason for women with normal ovary function to add r-LH in GnRH antagonist protocol.